{"id":3499,"date":"2017-12-01T09:21:35","date_gmt":"2017-12-01T14:21:35","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3499"},"modified":"2017-12-01T10:48:17","modified_gmt":"2017-12-01T15:48:17","slug":"denali-therapeutics-ipo-preview-dnli","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/denali-therapeutics-ipo-preview-dnli\/","title":{"rendered":"Denali Therapeutics #IPO Preview $DNLI"},"content":{"rendered":"

\"DenaliTherapeutics\"<\/a><\/p>\n

Company: Denali Therapeutics Inc<\/strong>
\nSymbol: DNLI
\nDescription: Their goal is to discover and develop therapeutics to defeat degeneration.
\nShares: 8.33 million
\nPrice Range: $17.00-$19.00
\nTrade Date: 12\/8
\nUnderwriter(s): Goldman Sachs, J.P. Morgan, Morgan Stanley
\nCo-Manager(s): Evercore ISI
\nFiled: 11-27-17<\/p>\n

Link to S-1\/A Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Business<\/strong>: Their\u00a0total portfolio currently consists of eleven programs. To prioritize the allocation of their resources, they designate certain programs as core programs and others as seed programs, and they\u00a0currently have six core programs and five seed programs. Their\u00a0core programs are at various stages of clinical and preclinical development. Their\u00a0most advanced core programs are their\u00a0LRRK2 inhibitor program to address Parkinson\u2019s disease and their\u00a0RIPK1 inhibitor program to address Alzheimer\u2019s disease and ALS. The two most advanced product candidates in their\u00a0LRRK2 program, DNL201 and DNL151, are potent, selective and brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson\u2019s disease. DNL201 is currently in a Phase 1 clinical trial in healthy volunteers in the United States. DNL151 has completed IND-enabling preclinical studies. They\u00a0submitted a CTA for DNL151 to the Netherlands Health Authority in October 2017 and it was accepted in November 2017. The most advanced product candidate in their\u00a0RIPK1 inhibitor program, DNL747, is a potent, selective and brain penetrant small molecule RIPK1 inhibitor product candidate for ALS and Alzheimer\u2019s disease. DNL747 is in IND-enabling preclinical studies and they\u00a0plan to submit a CTA in early 2018.<\/p>\n

Insider Buying:<\/strong>\u00a0Certain of their existing shareholders, including certain of their\u00a0directors and affiliates of their\u00a0directors, and their affiliated entities have indicated an interest in purchasing an aggregate of up to approximately $50.0 million of their\u00a0common shares in this offering at the initial public offering price per share.<\/p>\n

Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n

IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n

Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/span><\/a>\u00a0with our performance for last 12 years at our website.<\/p>\n

Indicate with confidence,\u00a0<\/b>SUBSCRIBE<\/b><\/a>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Company: Denali Therapeutics Inc Symbol: DNLI Description: Their goal is to discover and develop therapeutics to defeat degeneration. Shares: 8.33 million Price Range: $17.00-$19.00 Trade Date: 12\/8 Underwriter(s): Goldman Sachs, J.P. Morgan, Morgan Stanley Co-Manager(s): Evercore ISI Filed: 11-27-17 Link to S-1\/A Prospectus Link to Retail Roadshow Business: Their\u00a0total portfolio currently consists of eleven programs.[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1421],"class_list":["post-3499","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-dnli"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3499"}],"version-history":[{"count":6,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3499\/revisions"}],"predecessor-version":[{"id":3510,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3499\/revisions\/3510"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}